{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:16:44Z","timestamp":1790612204797,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Sanofi-Aventis, Warsaw, Poland"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.atherosclerosis.2018.01.036","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:55:13Z","timestamp":1517406913000},"page":"132-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland"],"prefix":"10.1016","volume":"270","author":[{"given":"Aleksandra","family":"Pelczarska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jakubczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Jakubiak-Lasocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Grucha\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Niewada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib1","unstructured":"Familial Hypercholesterolaemia: Identification and Management, Clinical Guideline [CG71], NICE [Internet]. https:\/\/www.nice.org.uk\/guidance\/cg71?unlid=666896701201512205758. (Accessed 19 December 2016)."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.01.036_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","article-title":"Familial hypercholesterolaemia: a global call to arms","volume":"243","author":"Vallejo-Vaz","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.07.007","article-title":"Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice","volume":"252","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","article-title":"Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration","author":"Vallejo-Vaz","year":"2016","journal-title":"Atherosclerosis Suppl."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2018.01.036_bib6","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2018.01.036_bib7","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia","volume":"36","author":"de Isla","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2018.01.036_bib8","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"39","key":"10.1016\/j.atherosclerosis.2018.01.036_bib9","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib10","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2018.01.036_bib12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/eurheartj\/ehv602","article-title":"Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death","volume":"37","author":"Krogh","year":"2016","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2018.01.036_bib13","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1053\/euhj.2002.3281","article-title":"Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands","volume":"23","author":"Marang-van de Mheen","year":"2002","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.01.036_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2004-822992","article-title":"Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands","volume":"4","author":"Wonderling","year":"2004","journal-title":"Semin. Vasc. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.01.036_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","article-title":"Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia","volume":"8","author":"Ademi","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijcard.2014.12.070","article-title":"Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States","volume":"181","author":"Chen","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"29","key":"10.1016\/j.atherosclerosis.2018.01.036_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4290","article-title":"Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis","volume":"4","author":"Marks","year":"2000","journal-title":"Health Technol. Assess."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.01.036_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1185\/03007990903494934","article-title":"Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia","volume":"26","author":"Nherera","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2018.01.036_bib19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/hrt.2010.213975","article-title":"Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies","volume":"97","author":"Nherera","year":"2011","journal-title":"Heart"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2018.01.036_bib20","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/eurheartj\/ehx111","article-title":"Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK","volume":"38","author":"Kerr","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.01.036_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0300-8932(09)70021-1","article-title":"Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia","volume":"62","author":"Oliva","year":"2009","journal-title":"Rev. Esp. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.01.036_bib22","first-page":"260","article-title":"Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia","volume":"11","author":"L\u00e1zaro","year":"2017","journal-title":"J.\u00a0Crim. Law"},{"issue":"36","key":"10.1016\/j.atherosclerosis.2018.01.036_bib23","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/eurheartj\/ehv289","article-title":"Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes","volume":"36","author":"Nanchen","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib24","doi-asserted-by":"crossref","DOI":"10.5551\/jat.37770","article-title":"Frequency of achilles tendon xanthoma in patients with acute coronary syndrome","author":"Harada","year":"2017","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.01.036_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2013.01.005","article-title":"Management of familial heterozygous hypercholesterolemia: position paper of the Polish lipid expert Forum","volume":"7","author":"Rynkiewicz","year":"2013","journal-title":"J\u00a0Clin Lipidol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.01.036_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2014.01.001","article-title":"Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum","volume":"8","author":"My\u015bliwiec","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib27","first-page":"127","article-title":"Young people's occupational activity on the labor market and their tendency to take up informal employment","volume":"3","author":"Pasternak-Malicka","year":"2014","journal-title":"J.\u00a0Econ. Meth."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib28","series-title":"Cardiovascular disease statistics","author":"Townsend","year":"2014"},{"issue":"Suppl.","key":"10.1016\/j.atherosclerosis.2018.01.036_bib29","first-page":"1115","article-title":"Prevalence of familial hypercholesterolemia in Poland in the LIPIDOGRAM2004 and 2006 population-based surveys","volume":"38","author":"Banach","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.01.036_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2017.64712","article-title":"PoLA\/cfpip\/pcs guidelines for the management of dyslipidaemias for family physicians 2016","volume":"13","author":"Banach","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familiar hypercholesterolemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A\u00a0review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5114\/aoms.2016.59700","article-title":"Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland","volume":"12","author":"Pajak","year":"2016","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.atherosclerosis.2005.02.016","article-title":"Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate","volume":"182","author":"Graham","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib35","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.110.979450","article-title":"Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children","volume":"123","author":"van der Graaf","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0022-2275(20)40754-0","article-title":"Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction","volume":"34","author":"Koivisto","year":"1993","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejim.2015.01.014","article-title":"Prevalence of DNA-confirmed familial hypercholesterolaemia in young patients with myocardial infarction","volume":"26","author":"Wald","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI107331","article-title":"Hyperlipidemia in coronary heart disease I. Lipid levels in 500 survivors of myocardial infarction","volume":"52","author":"Goldstein","year":"1973","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib39","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clinthera.2006.04.012","article-title":"Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization","volume":"28","author":"Cooke","year":"2006","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib41","series-title":"National Program for Equalization of Prevention and Treatment of Cardiovascular Disease POLKARD for 2013-2016","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib42","series-title":"Life Expectancy in 2015","year":"2016"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib43","first-page":"105","article-title":"Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management","author":"Scientific Steering Committee","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib44","series-title":"Poland's Health Status in 2014","year":"2016"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib45","series-title":"Health Survey for England, HS. 6","author":"Department of Health","year":"1996"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib46","series-title":"Morbidity and Mortality of Cardiovascular Diseases and the Demographic Situation of Poland","year":"2015"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.01.036_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/dia.2011.0092","article-title":"The Cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland","volume":"14","author":"Grzeszczak","year":"2011","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.20452\/pamw.1089","article-title":"Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results?","volume":"121","author":"Szmurlo","year":"2011","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5603\/KP.2013.0032","volume":"71","author":"Czech","year":"2013","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib50","doi-asserted-by":"crossref","first-page":"702","DOI":"10.5603\/KP.2013.0157","article-title":"Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project","volume":"71","author":"Sovic","year":"2013","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib51","series-title":"Requests for Reimbursement and Setting the Official Sales Price of Invokana (Canaglyphylsin) in Complex Oral Therapy for Type 2 Diabetes Treatment","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib52","series-title":"Request for Reimbursement and Setting the Official Sales Price of Januvia (Sitagliptin) for Adults with Type 2 Diabetes","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib53","series-title":"Request for Reimbursement and Setting the Official Sales Price of Lantus (Insulin Glargine) for Type 2 Diabetes Treatment","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib54","series-title":"Request for Reimbursement and Setting the Official Sales Price of Levemir (Insulin Detemir) for Type 2 Diabetes Treatment","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib55","unstructured":"Haldas M, Chudzicka A, Ziobro M, Rutkowski J, Glasek M, Lis J. JHPOR - Reaching Therapeutic Goals Impacts on Estimated Cost of Illness for Patients with Type 2 Diabetes in Poland. http:\/\/www.jhpor.com\/index\/artykul\/pokaz\/reaching_therapeutic_goals_impacts_on_estimated_cost_of_illness_for_patients_with_type_2_diabetes_in_poland. (Accessed 19 January 2017)."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib56","unstructured":"Order No. 86\/2005 of the President of the National Health Fund. Cervical Cancer Prevention Program, October 2005 R. http:\/\/www.nfz.gov.pl\/zarzadzenia-prezesa\/zarzadzenia-prezesa-nfz\/zarzadzenie-nr-862005,1750.html. (Accessed 19 January 2017)."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib57","unstructured":"Annual Consumer Price Index of Consumer Goods and Services since 1950, Central Statistical Office. http:\/\/stat.gov.pl\/obszary-tematyczne\/ceny-handel\/wskazniki-cen\/wskazniki-cen-towarow-i-uslug-konsumpcyjnych-pot-inflacja-\/roczne-wskazniki-cen-towarow-i-uslug-konsumpcyjnych-w-latach-1950-2014\/#. (Accessed 19 January 2017)."},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib58","series-title":"Health Technology Assessment Guidelines. Version 3.0","year":"2016"},{"key":"10.1016\/j.atherosclerosis.2018.01.036_bib59","series-title":"Statistical Yearbook of Labor, 2015","year":"2015"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018300364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018300364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:12:25Z","timestamp":1751274745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018300364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":59,"alternative-id":["S0021915018300364"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.01.036","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.01.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}